ADC Therapeutics SA Common Shares (ADCT) Covered Calls

You can sell covered calls on ADC Therapeutics SA Common Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ADCT (prices last updated Wed 11:45 AM ET):

ADC Therapeutics SA Common Shares (ADCT) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
4.41 0.00 4.40 4.42 69K - 0.3
Covered Calls For ADC Therapeutics SA Common Shares (ADCT)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
May 17 5 0.05 4.37 1.1% 23.6%
Jun 21 5 0.25 4.17 6.0% 42.1%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are ADCT-402, an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and ADCT-301, an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 and ADCT-602, as well as preclinical product candidates, including ADCT-701 and ADCT-901. ADC Therapeutics SA has a collaboration and license agreement with Genmab A/S. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.